Matti Lehtinen

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

Jorma Paavonen, Paulo Naud, Jorge Salmerón et al. · The Lancet · 2009 · 1.6K citations

As04-adjuvanted Vaccine, Gynecology, Oncogenic Hpv Types +16

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

Luisa L. Villa, Ronaldo Lúcio Rangel Costa, Carlos Alberto Petta et al. · The Lancet Oncology · 2005 · 1.6K citations

Vaccination, Vaccinology, Vaccine Development +9

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

Jorma Paavonen, David Jenkins, F. Xavier Bosch et al. · The Lancet · 2007 · 1.3K citations

Vaccination, Vaccine Safety, Interim Analysis +9

Human Papillomavirus Infection as a Risk Factor for Squamous-Cell Carcinoma of the Head and Neck

Jon Mork, A. Kathrine Lie, Eystein Glattre et al. · New England Journal of Medicine · 2001 · 942 citations · Full text

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

Luisa L. Villa, Ronaldo Lúcio Rangel Costa, Carlos Alberto Petta et al. · British Journal of Cancer · 2006 · 804 citations · Full text